title: Allogeneic bone marrow transplantation following busulfan-cyclophosphamide with or without etoposide conditioning regimen for patients with acute lymphoblastic leukaemia.
abstract: We have investigated the feasibility and efficacy of administering a radiation-free preparative regimen in the setting of allogeneic bone marrow transplantation (BMT) in 40 consecutive patients with acute lymphoblastic leukaemia (ALL). Busulfan (4 mg/kg/d x 4 d) and cyclophosphamide (50 mg/kg/d x 4 d) (BuCy4) were given in 29 patients and 11 received busulfan (4 mg/kg/d x 4 d), etoposide (60 mg/kg) and cyclophosphamide (60 mg/kg/d x 2 d) (BuCy+VP - 16). Median age was 22 years (range 1-50); 11 patients were children < or = 15 years of age. All children and 20 adults were at high risk of relapse pretransplant. Nine adults and one child died from transplant-related toxicity. 11 patients relapsed at a median of 11 months post-transplant (range 2-27). The 3-year Kaplan-Meier estimated probability of relapse was 42.1% and found to be significantly lower in patients with chronic GVHD (P = 0.03). 19 patients are leukaemia-free survivors with a median follow-up of 33 months (range 7-59). The Kaplan-Meier actuarial probability of disease-free survival at 3 years was 43% for all patients. 63.6% for children versus 30.2% for adults (P = 0.24) and 51.6% for patients transplanted in first remission versus 30.2% for those transplanted in subsequent remissions (P = 0.20).
authors.affiliation: Unité de Transplantation de Moelle Osseuse, Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada.
authors.forename: A
authors.initials: A
authors.lastname: von Bueltzingsloewen
authors.forename: R
authors.initials: R
authors.lastname: Bélanger
authors.forename: C
authors.initials: C
authors.lastname: Perreault
authors.forename: Y
authors.initials: Y
authors.lastname: Bonny
authors.forename: D C
authors.initials: DC
authors.lastname: Roy
authors.forename: J
authors.initials: J
authors.lastname: Boileau
authors.forename: J
authors.initials: J
authors.lastname: Kassis
authors.forename: R
authors.initials: R
authors.lastname: Lavallée
authors.forename: M
authors.initials: M
authors.lastname: Lacombe
authors.forename: M
authors.initials: M
authors.lastname: Gyger
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000379:methods* / Q000401:mortality; D002066:Busulfan / Q000008:administration & dosage; D002648:Child; D003520:Cyclophosphamide / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000401:mortality / Q000628:therapy*; D011292:Premedication; D012008:Recurrence; D014184:Transplantation, Homologous
chemical_list: D005047:Etoposide; D003520:Cyclophosphamide; D002066:Busulfan